The Trump administration is teaming up with French pharmaceutical company Sanofi to develop a vaccine for the new coronavirus disease COVID-19. The Department of Health and Human Services (HHS) said on Tuesday it would provide “expertise and reallocated funds” to support the vaccine’s development. Sanofi will partner up with the U.S. Biomedical Advanced Research and Development Authority—known as
Sanofi Pasteur has signed a deal with SK Chemicals to license cell culture vaccine technology as the US is hit by a flu epidemic, reportedly one of the worst in recent history, which has highlighted the need for a universal vaccine and more potent flu shots produced in cells instead of eggs. To get exclusive
Twice during last year, Sanofi has come up short in high-stakes attempts at top M&A prospects. Now, the drugmaker has finally bagged an acquisition, though not on the scale of its runs for Medivation or Actelion. Sanofi said on Tuesday that it’s picking up Connecticut-based flu vaccine maker Protein Sciences in a deal worth $650
